论文部分内容阅读
目的研究慢性胃溃疡及胃癌患者血清中转化生长因子β1(TGF-β1)和白介素-23(IL-23)的表达情况,探讨TGF-β1和IL-23在胃癌防治的临床价值。方法采用ELISA法检测胃癌组(83例)、胃溃疡组(184例)以及正常对照组(58例)血清TGF-β1和IL-23水平,并比较不同病理参数胃癌患者血清TGF-β1和IL-23水平的差异。结果胃癌组血清TGF-β1水平为(15.96±3.92)ng/mL、IL-23为(645.25±234.18)ng/mL,均高于正常对照组〔(9.87±2.86)ng/mL、(372.75±89.27)ng/mL〕和胃溃疡组〔(10.10±3.58)ng/mL、(496.10±108.32)ng/mL〕,差异均有统计学意义(P<0.05);胃癌Ⅰ~Ⅱ期、Ⅲ期及Ⅳ期患者血清TGF-β1水平依次升高,各期间差异均有统计学意义(P<0.05)。低分化胃癌血清TGF-β1水平高于高-中分化胃癌,有淋巴结转移者血清TGF-β1水平高于无淋巴结转移者,差异均有统计学意义(P<0.05);在不同肿瘤直径以及不同位置肿瘤患者血清TGF-β1水平差异无统计学意义(P>0.05)。Ⅰ~Ⅱ期胃癌患者血清IL-23水平高于Ⅲ期及Ⅳ期,差异有统计学意义(P<0.05);不同分化程度、淋巴结转移与否、不同肿瘤直径以及不同位置肿瘤患者血清IL-23水平比较差异均无统计学意义(P>0.05)。结论TGF-β1和IL-23在判定胃癌病理分期和恶性程度方面有重要的参考价值。
Objective To investigate the expression of TGF-β1 and IL-23 in serum of patients with chronic gastric ulcer and gastric cancer and to investigate the clinical value of TGF-β1 and IL-23 in the prevention and treatment of gastric cancer. Methods Serum levels of TGF-β1 and IL-23 in gastric cancer group (83 cases), gastric ulcer group (184 cases) and normal control group (58 cases) were detected by ELISA. The levels of serum TGF-β1 and IL-23 in gastric cancer patients with different pathological parameters -23 level of difference. Results Serum levels of TGF-β1 in gastric cancer group were (15.96 ± 3.92) ng / mL and (645.25 ± 234.18) ng / mL, respectively, which were significantly higher than those in normal control group (9.87 ± 2.86 ng / mL, 372.75 ± 89.27) ng / mL and gastric ulcer 〔(10.10 ± 3.58) ng / mL, (496.10 ± 108.32) ng / mL〕 respectively. There were significant differences between the two groups And the level of serum TGF-β1 in patients with stage Ⅳ in turn increased, the differences were statistically significant (P <0.05). The level of TGF-β1 in patients with poorly differentiated gastric cancer was higher than that in patients with high-moderately-differentiated gastric cancer, and the serum levels of TGF-β1 in patients with lymph node metastasis were significantly higher than those without lymph node metastasis (P <0.05). In different tumor diameters and in different There was no significant difference in the serum levels of TGF-β1 between patients with tumor location (P> 0.05). Serum levels of IL-23 in patients with stage Ⅰ-Ⅱ gastric cancer were significantly higher than those in patients with stage Ⅲ and Ⅳ (P <0.05), but different degrees of differentiation, lymph node metastasis or not, different tumor diameters and serum IL- 23 levels were no significant difference (P> 0.05). Conclusion TGF-β1 and IL-23 in the determination of gastric cancer staging and malignancy have important reference value.